Evotec
Barbara Bertani is a seasoned professional in medicinal chemistry, currently serving as VP and Head of Medicinal Chemistry 2 at Evotec in Verona since April 2019, after progressing from Senior Manager and Project Leader. Previous experience includes roles as Senior Research Leader at Aptuit and Lab Head in medicinal chemistry at Boehringer Ingelheim. Barbara's earlier career includes management positions at GlaxoSmithKline and GlaxoWellcome, where responsibilities spanned from laboratory-based synthetic chemistry to leading cross-functional teams in pre-clinical programs. Barbara holds advanced degrees in chemistry from the University of Milan, including a specialization in synthesis.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.